Human TARC/CCL17 ELISA Kit

For each experiment, a standard curve needs to be set for each microplate, and the specific OD value may vary depending on different laboratories, testers, or equipment. The following example data is for reference only. The sample concentration was calculated based on the results of the standard curve. The minimum detectable concentration of CCL17 is less than 3 pg/mL.

Serum Sample: TARC/CCL17 concentrations were measured in thirty-two human serum samples, which were collected from healthy human subjects. The measurements of thirty-two samples are in the range of 1000-4000pg/mL and shown in the figure below.

Serum Sample: TARC/CCL17 concentrations were measured in thirty-two human serum samples, which were collected from healthy human subjects. The measurements of thirty-two samples are in the range of 1000-4000pg/mL and shown in the figure below.

Three types of materials were tested to observe if there were matrix effect (interference). If the concentration of hemoglobin (simulated hemolysis) is less than 3500 mg/dL(2%), the concentration of triglyceride (simulated lipid blood) is less than 3 mg/mL, testing results will not be affected.

High concentrations of human TARC/CCL17 serum samples were diluted with 1:2, 1:4, 1:8 and 1:16 ratios for gradient dilution to evaluate the linearity of the assay. In the serum samples, the average detection rate of TARC/CCL17 was 97.89%.

Ten replicates of each of three samples containing different TARC/CCL17 concentrations were tested in one assay. Acceptable criteria: CV＜10%.

Three lots of samples containing different concentrations of TARC/CCL17 were tested in the independent assays. Acceptable criteria: CV

TARC/CCL17 was spiked into three human serum samples, and then analyzed. The average recovery of TARC/CCL17 for serum samples is 93.93%.